The company's molecular glue platform is built on using FKBPs as the presenter protein to target PPI of aberrant target proteins. Job responsibilities include managing the internal chemistry team, building the CRO network, structural biology/chemistry capabilities and consulting/advisor networks. Integral member of the target identification team. I manage budgeting, do presentations to the board, VCs and potential pharma partners, and responsible for visioning the company's future directions with our proprietary platform.

Leading drug discovery efforts and building out team and pipeline for an early stage biotech focused on small molecule drug discovery in oncology. Overseeing academic advisors, drug discovery consultants and CRO networks for the Barer Institute

Led Chemistry Consulting and CRO network for discovery stage oncology programs

Drug Discovery Program and Team Leadership• Full Program and Early Phase program leadership responsibilities covering a wide range of target classes – GPCRs (agonists, antagonists, allosteric modulators), proteases, ion channels, kinaseso Factor XIa (anti-thrombotic) – Program leader, delivering clinical candidates into development for the oral and parenteral programs Program Lead Factor XIa Program – team discovered Milvexian, currently in Phase II clinical trials and partnered with Janssen Pharmaceuticals. 2018 Ondetti-Cushman awardee (BMS’s highest scientific award) for team innovation for the FXIa program. o Program leader for multiple (>10) full phase programs, delivering 15 development candidates o Program leader for multiple (>20) early phase programs• Co-chair of the Heart Failure task force to identify exploratory targets for pipeline sustainability• Early development/clinical development team member for cardiovascular, thrombosis and metabolic disease clinical assets.• Identified, developed and implemented chemistry consulting networks to impact the internal chemistry community and third party review on business opportunities• Track record of developing program and scientific leadersBusiness Development, Academic Collaborations, External Partnerships• Discovery Lead for Business Development (asset/technologies) evaluationso Completed >100 evaluations in 5 years covering Oncology, Immunology, Fibrosis, Heart Failure and platforms/technologies.• Discovery partner to patent department on evaluating external patents as part of the due diligence process; includes working and guiding 3rd party Patent Attorneys through FTO and patentability decisions.• Discovery Chemistry leader for the BMS-Princeton and BMS-Scripps Research academic collaborations.• Lead Discovery Chemist on External Alliances -Allied Minds-BMS Life Sciences, BMS-Galecto, BMS-Solvay• Integration Lead for Medicinal Chemistry – BMS/Celgene Acquisition